#Thrombin Inhibitor Market

[writerblogs]

Global Thrombin Inhibitor Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of Blood Disorders

The global Thrombin Inhibitor market is estimated to be valued at US$ 1.86 billion in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Thrombin inhibitors are medications that prevent the formation or action of thrombin, a protein involved in blood clotting. These inhibitors are used to treat various blood disorders such as deep vein thrombosis, pulmonary embolism, atrial fibrillation, and myocardial infarction. Thrombin inhibitors offer several advantages, including reducing the risk of clot formation, preventing clot growth, and decreasing the likelihood of clot-related complications such as strokes or heart attacks. The growing prevalence of blood disorders and the need for effective treatment options are driving the demand for thrombin inhibitors in the market. Market Key Trends: One key trend in the thrombin inhibitor market is the increasing adoption of oral anticoagulant drugs. Oral anticoagulants, also known as direct oral anticoagulants (DOACs), are emerging as a preferred treatment option over traditional warfarin therapy. DOACs offer several advantages such as predictable anticoagulant effects, reduced risk of bleeding complications, and minimal drug-food interactions. For example, drugs like apixaban and rivaroxaban have gained significant popularity due to their efficacy and ease of use compared to warfarin. The increasing adoption of oral anticoagulants is expected to drive the growth of the thrombin inhibitor market. PEST Analysis: Political: The political landscape plays a crucial role in shaping regulations and policies related to the pharmaceutical industry. Government regulations regarding drug approvals, pricing, and reimbursement policies can impact the growth of the thrombin inhibitor market. Technological: Technological advancements in the field of drug development and diagnostics have led to the introduction of innovative thrombin inhibitors. The development of targeted therapies and personalized medicine approaches enhances treatment outcomes and patient satisfaction. Key Takeaways: 1. The global Thrombin Inhibitor Market is expected to witness high growth, exhibiting a CAGR of 5.8% over the forecast period. The increasing prevalence of blood disorders, coupled with the need for effective treatment options, is driving market growth. 2. North America is anticipated to be the fastest-growing and dominating region in the thrombin inhibitor market due to the high incidence of chronic diseases and favorable healthcare infrastructure. Europe is also expected to have significant market growth. 3. Key players operating in the global thrombin inhibitor market include Pfizer Inc., Bristol Myers Squibb, Bayer AG, Sanofi S.A., Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company, Limited, CSL Behring, Portola Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Aspen Pharmacare Holdings Limited, and Eisai Co., Ltd. These companies focus on research and development activities, strategic collaborations, and product launches to strengthen their market position. In conclusion, the global thrombin inhibitor market is poised for significant growth due to the increasing prevalence of blood disorders and the adoption of oral anticoagulants. The market is influenced by political, economic, social, and technological factors. Key players in the market strive to innovate and collaborate to meet the growing demand for effective thrombin inhibitor therapies.

[tushar38]

Anticoagulant reversal drugs are critical in managing bleeding complications associated with anticoagulant therapy. These drugs work by counteracting the effects of anticoagulants, which are prescribed to prevent blood clots. Commonly used anticoagulant reversal agents include vitamin K for warfarin, protamine sulfate for heparin, and specific reversal agents like idarucizumab for direct thrombin inhibitors and andexanet alfa for factor Xa inhibitors. The development of these reversal drugs has significantly improved patient outcomes by allowing for rapid intervention in cases of excessive bleeding or emergency surgery. Ongoing research aims to enhance the efficacy, safety, and accessibility of these vital therapeutic agents.

[delveinsight12]

Factor Xa Inhibitor Market to Witness Growth by 2032 | Bayer, Novartis, GSK

DelveInsight's "Factor Xa Inhibitor Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Factor Xa Inhibitor, historical and forecasted epidemiology as well as the Factor Xa Inhibitor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Factor Xa Inhibitor market report provides current treatment practices, emerging drugs, Factor Xa Inhibitor market share of the individual therapies, and current and forecasted Factor Xa Inhibitor market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Factor Xa Inhibitor treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of opportunities and assesses the underlying potential of the Factor Xa Inhibitor market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/factor-xa-inhibitor-market

Factor Xa Inhibitor Overview

Factor Xa inhibitors are a class of anticoagulant medications that work by inhibiting the activity of factor Xa, which is a key enzyme involved in the blood clotting process. These medications are commonly used for the prevention and treatment of various thromboembolic disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke in patients with atrial fibrillation.

Factor Xa inhibitors include medications such as rivaroxaban, apixaban, edoxaban, and betrixaban. They prevent the formation of blood clots by interfering with the conversion of prothrombin to thrombin, thereby reducing the formation of fibrin, which is essential for clot formation.

Factor Xa Inhibitor Causes:

Factor Xa inhibitors are typically prescribed in patients with conditions that increase the risk of blood clot formation, such as atrial fibrillation, deep vein thrombosis, pulmonary embolism, or those undergoing certain surgical procedures. They are also used for stroke prevention in patients with atrial fibrillation and for the treatment of venous thromboembolism.

Factor Xa Inhibitor Signs and Symptoms:

While factor Xa inhibitors are effective in preventing blood clots, they can also increase the risk of bleeding, which is the primary concern associated with these medications. Signs and symptoms of bleeding may include:

Unexplained or excessive bruising

Nosebleeds

Bleeding gums

Prolonged bleeding from cuts

Blood in urine or stools

Vomiting blood or material that looks like coffee grounds

Severe headaches or dizziness

Weakness or fatigue

Factor Xa Inhibitor Treatment Options:

If bleeding occurs while taking factor Xa inhibitors, immediate medical attention is necessary. Treatment options for bleeding associated with factor Xa inhibitors may include:

Stopping or temporarily discontinuing the factor Xa inhibitor medication.

Administering specific reversal agents such as andexanet alfa (Andexxa) for apixaban and rivaroxaban.

Blood transfusions to replace lost blood volume and clotting factors.

Surgical intervention in severe cases to control bleeding.

Learn more about Factor Xa Inhibitor, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/factor-xa-inhibitor-market

Factor Xa Inhibitor Market 

The Factor Xa Inhibitor market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Factor Xa Inhibitor market trends by analyzing the impact of current Factor Xa Inhibitor therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Factor Xa Inhibitor market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Factor Xa Inhibitor market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Factor Xa Inhibitor market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:

Factor Xa Inhibitor Epidemiology 

The Factor Xa Inhibitor epidemiology section provides insights into the historical and current Factor Xa Inhibitor patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Factor Xa Inhibitor market report also provides the diagnosed patient pool, their trends, and assumptions undertaken. 

Factor Xa Inhibitor Drugs Uptake

This section focuses on the uptake rate of the potential Factor Xa Inhibitor drugs recently launched in the Factor Xa Inhibitor market or expected to be launched in 2019-2032. The analysis covers the Factor Xa Inhibitor market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Factor Xa Inhibitor Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Factor Xa Inhibitor market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Factor Xa Inhibitor Pipeline Development Activities

The Factor Xa Inhibitor report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Factor Xa Inhibitor key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Factor Xa Inhibitor pipeline development activities at: https://www.delveinsight.com/report-store/factor-xa-inhibitor-market

Factor Xa Inhibitor Therapeutics Assessment

Major key companies such as Bayer, Novartis, GSK, and others are working proactively in the Factor Xa Inhibitor Therapeutics market to develop novel therapies which will drive the Factor Xa Inhibitor treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/sample-request/factor-xa-inhibitor-market

[omkarpatel]

Bovine Plasma Market is Estimated to Witness High Growth Owing to Rising Demand for Plasma Derived Proteins

Bovine plasma contains proteins that are used to manufacture life-saving medications. It is a byproduct of beef industry collected from licensed slaughterhouses. The proteins found in bovine plasma are used to develop therapies for immune deficiencies, bleeding disorders, and other medical conditions.

Market Dynamics: Bovine plasma market is driven by rising demand for plasma derived proteins.Plasma proteins play a vital role in various therapeutic areas due to their unique biochemical properties and physiological functions. Growing use of plasma proteins in various biopharmaceutical applications such as immune globulins, thrombin, factor VIII, albumin and others is expected to boost the bovine plasma market growth over the forecast period. Moreover, investments by key players for expanding plasma derived therapeutics production is also expected to fuel the market growth during 2023-2030.

Increasing Demand for Plasma Derived Products from Pharmaceutical Industry The global bovine plasma market is primarily driven by the increasing demand for plasma derived products from the pharmaceutical industry. Plasma derived products such as immunoglobulins, albumin, fibrinogen concentrates, and protease inhibitors are extensively used in various therapeutics areas including infectious disease, bleeding disorders, immunology, and metabolic disorders. Rising prevalence of chronic diseases globally has further augmented the demand for plasma derived pharmaceutical products. According to estimations, diseases requiring plasma therapies are increasing at annual rate of approximately 5% worldwide. Additionally, advancements in plasma fractionation technologies have enabled efficient plasma separation and blood-derived product development, thereby expanding the production capabilities of plasma derived pharmaceuticals. Growing aging population prone to chronic illnesses also acts as a favorable factor for bovine plasma market growth.

Stringent Regulations Regarding Safety and Quality Standards of Plasma Collection and Derivative Products Stringent regulations imposed by regulatory authorities regarding the safety, quality, and standardization of bovine plasma collection and derivative products act as a major market restrain. The collection, testing, manufacturing, and distribution of bovine plasma products are highly regulated by international organizations as well as local regulatory bodies. Regulatory agencies focus on adherence to current good manufacturing practices, proper donor selection criteria, pathogen inactivation and removal steps, product shelf life and labeling requirements. Strict quality process controls and sterility testing during plasma fractionation ensure generation of safe therapy-grade plasma derivatives. However, continuous updates in existing guidelines and compliance with varied regulatory frameworks across countries increase the manufacturing and production costs for plasma companies. Resource intensive regulatory compliance procedures thus add operational challenges for players in bovine plasma market.

Opportunities in Developing Markets Fueled by Growing Healthcare Infrastructure Developing economies in Asia Pacific and Latin America present lucrative opportunities for participants in the global bovine plasma market. Rapid economic growth and improving consumer disposable incomes in these regions have augmented healthcare spending. Concurrent government focus on enhancing healthcare infrastructure and access to modern medical facilities also supports the clinical demand for plasma derived products. Emerging nations now account for over 80% of the global disease burden, indicating vast unmet need for therapies derived from bovine plasma. Moreover, several multinational companies are shifting their manufacturing units to developing markets owing to availability of relatively cheaper resources and talent pool. This allows production and supply of affordable plasma therapies further driving bovine plasma usage. Initiatives toward increasing plasma collection centers and fractionation facilities especially in densely populated developing countries will stimulate bovine plasma market revenues during the forecast period.

Rising Penetration of Recombinant and Biosimilar Therapy Alternatives While the demand for bovine plasma derived therapeutics continues growing, rising penetration of recombinant and biosimilar therapy alternatives also poses a notable trend. Increasing R&D investments by leading pharmaceutical corporations in cell culture and bioprocess technologies have enabled production of recombinant therapy substitutes on industrial scale. For instance, genetically engineered versions of albumin and clotting factors are being developed as safer alternatives to bovine plasma derivatives. Biosimilars and follow-on biologics are also emerging as cost-effective options in therapeutic areas including immunology and hematology. Regulatory approvals and favorable pricing of biosimilars compared to reference plasma therapies will likely encourage their uptake in coming years. This shifts a part of the demand away from conventional bovine plasma products impacting their sales potential. Nonetheless, the growing disease burden and need for immune globulins worldwide will sustain substantial requirements for bovine plasma market.

[latestindustryreports]

Coagulation Market Segmentation, Competitive Landscape and Industry Poised for Rapid Growth 2030

The market research conducted by The Insight Partners- “Global Coagulation Market Size Report | Industry & Analysis - 2030” intends to present business-oriented market insights to investors. Beyond operational factors, this research includes future market projections. Along with drivers, and challenges this report covers a range of opportunities available for Coagulation market participants. Both primary and secondary research methods have been used to frame valid facts included in this research.

Coagulation Market research deep dive into several segments to offer a comprehensive outlook to both veteran and new entrants. Through this market research companies can get a better perspective and understanding of the target audience and ensure the company gets a competitive edge. It is vitally important for companies to understand the market before investing in large proportions. Spending a small share of your business investment on trustworthy market research makes business sense.

The competition landscape covered in this research is important for businesses to adopt eye open approach. This market research offers unbiased insights that can be used by companies to learn their strengths and weaknesses. Capitalizing on new-found insights from competitor’s analysis will be an advantage for companies to forge ahead.

Coagulation Market research report could be the foundation of your business strategy as it includes pieces of evidence of market investigation which offers the best chance for business to achieve their business goals.

Key objectives of this research are:

Global Coagulation Market Dynamics- Market Share, Market Size, and CAGR

To Analyze Drivers, Challenges, and Opportunities in Coagulation Market

To offer a competitive landscape- Strategies by key players

To present strategic Coagulation market recommendations for investors.

To offer a brief account of customer needs, target demographics, and regional scope.

To help businesses in the evaluation of success against the Coagulation market benchmarks.

COVID-19 Impact Analysis

Covid-19 began as a health crisis and turned into an economic one, shaking the business world. The period marked a drop-down in revenue scales and led to the suspension of production for a certain time. This section under Coagulation market research dedicated to a detailed discussion on pandemic influences and responses by businesses is intended to help companies in post-pandemic business tactics. After 2 years of disrupted supply-demand metrics, participants in the Coagulation market started to reposition themselves back in competition. Key companies in this Coagulation market are- .

What are the Perks for Buyers of this Report

Detailed overview of current Coagulation market situation.

Precisely estimated market revenue projections and CAGR to streamline resources.

Regional coverage to uncover new markets for business

Competition analysis intends to help companies in a competitive edge.

Facts-based crystal clear insights for business success.

The research is customized as per business requirements.

Access to PDF, and PPT formats of this research.

Market Segmentation-

Based on Disease Indications of Coagulation Market Research report:

Vitamin K Deficiency

Liver Disease

Disseminated Intravascular Coagulation & Pulmonary Embolism

Development of Circulating Anticoagulants

Hemophilia

Based on Treatment of Coagulation Market Research report:

Anti-Fibrinolytic Drugs

Birth Control Pills

Desmopressin & Immunosuppressive Medicines

Vitamin K Supplements

Blood Thinners

Thrombin Inhibitors or Thrombolytics

Replacement Therapy

Based on Technology of Coagulation Market Research report:

Optical Technology

Mechanical Technology

Electrochemical Technology

Others

Based on Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of Latin America)

The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)

Rest of the World…

[healthcare-market]

Cell Culture Market : Technological Growth Map with an Impact-Analysis

Cell Culture Market: Introduction

According to the report, the global cell culture market was valued at US$ 10.5 Bn in 2020 and is projected to expand at a CAGR of 9% from 2021 to 2031. The global cell culture market is driven by development of new products, technological advancements, and increase in use of single-use bioprocessing systems during the forecast period. The cell culture market in Asia Pacific is anticipated to expand at the fastest CAGR during the forecast period due to high unmet clinical needs, improvements in the healthcare infrastructure, and increase in focus on research & development activities.

Rise in Demand and Approvals for Biosimilar Products & Other Biologic Therapeutics to Drive Market

Cell culture is one of the most important steps for the production of biosimilar antibodies, as cell culture helps increase efficiency & productivity and reduce the cost of manufacture. The increase in demand & approvals for biosimilars products and other biologic therapeutics for the treatment of chronic diseases in developed as well as developing countries has led to the demand for efficient and cost-effective products. This is expected to drive the global cell culture market during the forecast period.

Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=405

Moreover, rise in demand for cost-effective and highly efficient cell culture products such as bioreactors, media, reagents, and sera for the production of high-yield cell lines has led to a surge in the number of new product launches. This is likely to provide lucrative opportunities in the global cell culture market during the forecast period. Major manufactures strive to expand their product portfolio by launching new and advanced systems for large-scale production, which is cost-effective and has low risk of contamination.

For instance, in 2018, Merck launched capsule filters that are designed to decrease the risk of contamination in a bioreactor. These filters are used for the separation of mycoplasma and bacteria from cell culture media. However, ethical issues associated with the use of fetal bovine serum, stringent regulations, and high cost of infrastructure for cell culture are projected to hamper the growth of global cell culture market during the forecast period.

Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=405

Technological Advancements in Cell Culture Production Media & Instruments to Drive Demand for Protein-based Therapeutics

In terms of product, the global cell culture market has been classified into instruments, media, sera, and reagents. The instruments segment has been categorized into cell culture vessels (bioreactors), carbon dioxide incubators, biosafety cabinets, cryogenic tanks, and others. Technological advancements for improving the efficiency and reducing the risk of cross contamination are anticipated to propel the instruments segment during the forecast period.

The media segment has been split into chemically defined, classical media, protein free media, Lysogeny media, serum free media, and specialty media. The efficiency of different media used for cell culture production is expected to drive the media segment over the next few years.

The sera segment has been bifurcated into fetal bovine serum and others. Sera are used as cell culture supplements consisting of growth factors, nutrients, and other important trace elements. The reagents segment has been segregated into albumin, amino acid, attachment factors, growth factors & cytokines, protease inhibitor, thrombin, and others. Applications such as stem cell research have vast potential in future. Stem cell culture assists in standardization of drug production and enables production of a number of cell lines & related products.

Traditional pharmaceutical therapeutics help in treating only disease symptoms, whereas stem cell therapies assist in treating the cause of the disease. Hence, further research in the field of stem cell culture for development of drugs presents significant opportunities in the market in the near future.

Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=405

Increase in Usage of Cell Culture Products in Drug Development & Manufacturing to Propel Pharmaceutical Companies Segment

Based on end-user, the global cell culture market has been divided into biotechnology companies, pharmaceutical companies, academic institutes, and research institutes. The pharmaceutical companies segment dominated the global market in 2020, and the trend is anticipated to continue during the forecast period due to increase in usage of cell culture products in drug development and manufacturing. The biotechnology companies segment is expected to account for a significant market share by 2031. The growth of the segment can be attributed to increase in the number of biotechnology companies and rise in strategic collaborations among market players to expand global presence.

Asia Pacific to Dominate Global Market

In terms of region, the global cell culture market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for a major share of the global market during the forecast period, owing to the presence of key players, increase in research & development activities, and new drug approvals.

Shift in trend toward continuous processing is expected to drive the cell culture market in North America. The cell culture market in Asia Pacific is at a pivotal point. Increase in focus of key players on expansion in the region, large untapped population, and rise in awareness about healthcare augment the cell culture market in Asia Pacific. For instance, Thermo Fisher expanded its Fisher BioServices and cryogenic service capabilities in Japan.

Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=405

Thermo Fisher Scientific and Merck KGaA to Lead Global Market

Key players covered in this report are Sartorius AG, Thermo Fisher Scientific, Inc., Eppendorf AG, GE Healthcare, Corning Incorporated, Becton, Dickinson and Company, Merck KGaA, Lonza, VWR International, LLC, and PromoCell GmbH. Companies operating in the global cell culture market focus on strategic collaborations for developing new products in the emerging markets such as Asia Pacific and Latin America.

For instance, in May 2017, Merck announced the launch of EX-CELL Advanced HD perfusion medium, which helps increase the production yield and streamline the regulatory compliances.

About Us 

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact

Nikhil Sawlani Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453

[maisuria]

How Roche’s HEMLIBRA will help in the Hemophilia Treatment Landscape?

Hemophilia A Treatment Landscape

Despite historical ups and downs,hemophilia A patient treatment has significantly improved over the past 40 years. The modern advancement of hemophilia therapies began with the revolutionary discovery of cryoprecipitate in 1964. Several years later, scientists discovered that plasma-derived factors are focused on FVIII products. This category saw the approval of a number of hemophilia A drugs that were easier to administer than cryoprecipitate or fresh-frozen plasma, such as FEIBA (Pfizer), MONOCLATEP (CSL Behring), and HEMOFIL-M. The development of recombinant therapy in the 1980s changed the situation for those who have hemophilia A.

There were only short half-life (SHL) recombinant medicines available prior to the approval of the first extended half-life (EHL) in the US (ELOCTATE; 2014). Other treatments avoid using the inhibitor-specific drugs utilized in hemophilia A. One of the most profitable bypass agents is Novonordisk's NOVOSEVEN, which holds the majority of the hemophilia A market share in comparison to Takeda's FEIBA and OBIZUR (not yet approved in Japan). Due to the adoption and use of EHL treatments, which reduced the frequency of injection to a deplorable level, the market for plasma-derived FVIII has already fallen and sales of SHL products have started to decline.

HEMLIBRA: Target patient population and strong uptake

The hemophilia A market products have remained quite fragmented because no one therapy has been able to capture a sizable portion of the market; however, the release of HEMLIBRA in 2017 changed this situation. With or without factor VIII inhibitors, HEMLIBRA, a bispecific factor IXa and factor X-directed antibody, is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency), who are aged newborn and older. For hemophilia A patients taking inhibitors, HEMLIBRA was first approved in the US (November 2017), then in Europe (February 2018), and finally in Japan (March 2018).

Patients Switching to HEMLIBRA

For the non-inhibitor market, HEMLIBRA was introduced in 2018, and the hemophilia The significant uptake of HEMLIBRA over the past few years, where it crossed a billion in opportunity in 2019, makes it clear that a patient share has started to shift from EHL medicines to HEMLIBRA. HEMLIBRA had 17,000 patients receiving treatment worldwide as of the first quarter of 2022, according to the Global Pharma Survey 2022.

Factors contributing to Patient Switching to HEMLIBRA

Patients move to HEMLIBRA primarily on the advice of their doctors; at the moment, 50–60% of doctors view HEMLIBRA as the first-line hemophilia A treatment. Low administration frequency (as little as once per month) and longer reaction times are the key drivers of patient switching and doctor referrals.

Upcoming competition for HEMLIBRA

Fitusiran, a small interfering RNA treatment from Sanofi that is approved and delivered subcutaneously, is anticipated to hit the US market in 2025. A siRNA called fitusiran is made to reduce antithrombin levels in order to encourage enough thrombin production to stop bleeding. One of the main benefits of this therapy is that it can be administered once or twice a month to patients with hemophilia A or B. Despite this, we are still dubious about the drug's future due to safety concerns.

Additional hemophilia A therapies are expected to reach the 7MM in the following years and address the unmet needs of hemophilia A patients, including Valrox (Biomarin Pharmaceutical), BIVV001 (Sanofi), SPK-8011 (Roche/Spark Therapeutics), and giroctocogene fitelparvovec (Pfizer/Sangamo Therapeutics).

Related Reports:

Ventricular Assist Devices Market 

"DelveInsight’s ‘Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast – 2027’ report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market 

DelveInsight’s ‘Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Basal Cell Carcinoma (Basal Cell Epithelioma) Market 

DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Latest Reports by DelveInsight

Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market |  Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market

To know more about our Competitive Services, Click here: Pharma Competitive Intelligence

Also, take a glance at the Blogs by DelveInsight:

How Metaverse is Set to Transform the Healthcare Dynamics?

Role of Mobile Technology in Hemophilia Management

How 3D Bioprinting Technology is Revolutionizing the Healthcare Industry?

How Cloud Computing is Transforming the Healthcare Industry Dynamics?

Despite historical ups and downs,hemophilia A patient treatment has significantly improved over the past 40 years. The modern advancement of hemophilia therapies began with the revolutionary discovery of cryoprecipitate in 1964. 

Get to know more about the hemophilia A patient treatment landscape through our blog -https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

[chris-harris-blog]

Thrombin Inhibitor Market : Drivers, Restraints, Opportunities, and Threats (2021-2027) | by Bristol-Myers Squibb, Microbix Biosystems, Sanofi

Thrombin Inhibitor Market : Drivers, Restraints, Opportunities, and Threats (2021-2027) | by Bristol-Myers Squibb, Microbix Biosystems, Sanofi

The Global Thrombin Inhibitor Market is anticipated to rise at a considerable rate during the forecast period. In the recent years, the market was growing at a steady rate and with the rising adoption of strategies by key players; the Thrombin Inhibitor market is expected to rise over the Forecast Period of 2020-2027. Book NOW! PDF of Sample Research Report, Today Report Scope: Top Manufacturers…

[thekwandae-blog]

Value and Size Of Thrombin Inhibitor Market From 2020 To 2025: Detailed Research Report

Estimating the potential size of the Thrombin Inhibitor Market The market intelligence report analysis provides a comprehensive insight into the global Thrombin Inhibitor channel. The  Thrombin Inhibitor Market wraps up-to-date industry data on the real and potential Market situation, segmentation, competitive landscape, regional breakdowns, and future outlook. The Thrombin Inhibitor market industry research report comprises an innovative tool in order to evaluate the overall scenario of industry along with its opportunities and supporting strategic decision-making. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Thrombin Inhibitor market. This report also focused on SWOT, P.E.S.T.L.E., and Porter’s Five Forces analyses of the global Thrombin Inhibitor market. The report answers questions related to the market improvement condition, business circumstance, recent improvements,  measure, and pathways of Thrombin Inhibitor that makes this report so advantageous for the pioneers and the new candidates in the Industry. The overview, SWOT analysis and strategies of each vendor in the Thrombin Inhibitor market provide understanding about the market forces and how those can be exploited to create future opportunities. Each section of the research study is specially prepared to explore key aspects of the global Thrombin Inhibitor market. Extensive assessment of the global Thrombin Inhibitor market 2020 covers the historical analysis of the market from 2014 to 2019 and derives authentic and reliable forecast estimations up to 2025 based on several segments and regions. To Obtain All-Inclusive Information – Download Sample Copy of Thrombin Inhibitor Market Report Study 2020-2025 at www.empiricaldatainsights.com/sample-request/8025/ Competitive Landscape: This section offers information about the competitive landscape among the top players in the Thrombin Inhibitor market. Though several new vendors are entering the Thrombin Inhibitor market, they find it difficult to compete with international vendors based on factors such as quality, features, functionalities, and services.  It also contains company profiles, revenue and financial details, product portfolio, and strategies, mergers & acquisitions, and partnerships, etc. Prominent Players in Thrombin Inhibitor are who leading the market throughout the globe are covered in the report: Bristol-Myers Squibb, Bayer, Sanofi, Genentech, CSL, Abbott, Armetheon, Microbix Biosystems, Astrazeneca, Baxter, Emisphere Technologies, Johnson & Johnson, Merck Global Thrombin Inhibitor Market Segmentation on the basis of Type, Application, And Region: The market study includes insights on segmentation by product type: Argatroban, Activase, Others On the basis of Application of Thrombin Inhibitor Market can be split into: Hospital, Specialist Clinic, Others In this study, the years considered to estimate the market size of Thrombin Inhibitor are as follows: History Year: 2014-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year 2020 to 2025 This report splits the global market into several key Regions, with market size and end users are analyzed as well as segment markets by types, applications and companies in these regions,  from 2020 to 2025 (forecast), like Americas (United States, Canada, Mexico, Brazil) Europe (Germany, France, UK, Italy, Russia, Spain) APAC (China, Japan, Korea, Southeast Asia, India, Australia) Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries) Questions Answered in Global Thrombin Inhibitor Market Report 2019: – What will be the Thrombin Inhibitor market size in 2025? – What will be the growth rate? – What are the major Thrombin Inhibitor market trends? – What is urging Thrombin Inhibitor market? – Who are the outstanding vendors in the world Thrombin Inhibitor market? – What are the challenges to Thrombin Inhibitor market growth? – What are market trends striking the growth of the Thrombin Inhibitor industry? For More Information on This Report, Please Visit @ https://www.empiricaldatainsights.com/industry-report/thrombin-inhibitor-market/8025/ Finally,  researchers throw light on the pinpoint analysis of Global Thrombin Inhibitor dynamics. It gives a review of Thrombin Inhibitor showcase, containing worldwide income, worldwide generation, deals, and CAGR. The estimate and examination of Thrombin Inhibitor advertise by sort, application, and area are likewise introduced in this part. It is about the market scene and real players. About us: An optimally formulated blueprint is the main essence of a successful business. To prepare a similar blueprint - accurate and well-informed data is required to make simplified decisions. We at Empirical Data Insights assimilate the same quality of data through our discreetly prepared market reports. Providing the right data to businesses and cater to the process of decision making or capturing markets, is what we aim to do. Our reports will prove to be useful in each & every step of the chain and business process. Contact Us: Mach Lewis 555 Madison Avenue, 5th Floor, Manhattan, New York, 10022 USA Phone No.: +1 (800) 663-5579 Email ID: sales@empiricaldatainsights.com

[leftcomputerpost]

Heparin-Induced Thrombocytopenia (HIT) Treatment Market - Future Scenario, Key Insights, Top Companies 2029

Heparin-Induced Thrombocytopenia (HIT) Treatment Market Overview

Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated life-threatening complication. It is an adverse drug reaction caused by the generation of antibodies that activates platelet factor 4(PF-4) in the presence of heparin. Heparin-Induced Thrombocytopenia (HIT) can lead to many thromboembolic complications, such as acute myocardial infarction, pulmonary embolism, deep venous thrombosis, thrombotic stroke and pulmonary embolism. A number of laboratory tests like Enzyme-Linked Immunosorbent Assay (ELISA), Serotonin Release Assay (SRA), Enzyme Immunoassay (EIA), Heparin-Induced Platelet Activation (HIPA) Tests are now available to confirm the diagnosis of Heparin-induced thrombocytopenia (HIT) treatment. Heparin-Induced Thrombocytopenia (HIT) treatment can be mediated by three alternative anticoagulants. These include Lepirudin, Danaparoid and Argatroban. These antithrombotic drugs are immediately active and are direct inhibitors of thrombin. They also inhibit thrombin generation and are routinely monitored. These drugs are monitored with ecarin the clotting time (ECT) for lepirudin, the activated clotting time (ACT) for argatroban, or anti?Xa assays for danaparoid. However, consideration should be given towards the safety and efficacy of the alternative anticoagulant drug for the heparin-induced thrombocytopenia (HIT) treatment. The patient’s clinical status including renal and hepatic function, likely risks and benefits should be monitored during the heparin-induced thrombocytopenia (HIT) treatment.

Heparin-Induced Thrombocytopenia (HIT) Treatment: Drivers and Restraints

Increase administration of various forms of heparin, an anticoagulant for the treatment of cardiovascular and orthopaedic surgery and invasive procedures increase the chances of heparin-induced thrombocytopenia, which drives the heparin-induced thrombocytopenia (HIT) market. Heparin is widely being used in acute coronary syndromes, atrial fibrillation, venous thromboembolism, dialysis, peripheral occlusive disease, and during extracorporeal circulation which increase the chances of heparin-induced thrombocytopenia (HIT) and drives the market of heparin-induced thrombocytopenia (HIT) treatment. About 12 million hospitalized patients in the USA, around one third in a year, are receiving heparin, which is expected to drive the heparin-induced thrombocytopenia (HIT) treatment market. However, due to the various complications of heparin-induced thrombocytopenia (HIT) treatment and side effects of the available drugs expected to restraints the heparin-induced thrombocytopenia (HIT) treatment market.

Heparin-Induced Thrombocytopenia (HIT) Treatment: Overview

The growth of heparin-induced thrombocytopenia (HIT) treatment market is expected to be high during forecasting periods due to the life-threatening complication of the disease. Increasing administration of heparin develops the possibilities of life-threatening heparin-induced thrombocytopenia (HIT), which will drive the heparin-induced thrombocytopenia (HIT) treatment market. However, due to the less availability of sophisticated drugs and therapies, there is a huge opportunity among the key market players for the development of novel drug and therapies for the heparin-induced thrombocytopenia (HIT) treatment during the near forecasting periods.

Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Region-wise Outlook

U.S. is expected as the largest regional market share in the heparin-induced thrombocytopenia (HIT) treatment market owing to high patient awareness levels, the presence of more number of market players, increasing awareness about heparin-induced thrombocytopenia (HIT) treatment and marketing activities in the region followed by Europe. The heparin-induced thrombocytopenia (HIT) treatment market is expected to grow fastest in the Asia Pacific may because of the increasing prevalence of cardiovascular and acute coronary syndromes, thus boosting the market growth. However, in the South Asian countries such as India and China, the opportunities to manufacture and distribute new heparin-induced thrombocytopenia (HIT) treatment drugs is expected to be higher due to large population and increasing incidence of heparin-induced thrombocytopenia during forecasting periods.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-10978

Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Key Market Participants

Key players of heparin-induced thrombocytopenia (HIT) treatment market includes Pfizer Inc., Alleviare Life Sciences Pvt. Ltd., ANDOZ, GlaxoSmithKline Plc., Eagle Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd., WEST-WARD, INC among others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Heparin-Induced Thrombocytopenia (HIT) Treatment Market Segments

Heparin-Induced Thrombocytopenia (HIT) Treatment Market Dynamics

Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size

Heparin-Induced Thrombocytopenia (HIT) Treatment Supply & Demand

Heparin-Induced Thrombocytopenia (HIT) Treatment Current Trends/Issues/Challenges

Heparin-Induced Thrombocytopenia (HIT) Treatment Competition & Companies involved

Heparin-Induced Thrombocytopenia (HIT) Treatment Technology

Heparin-Induced Thrombocytopenia (HIT) Treatment Value Chain

Regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain)

Eastern Europe (Poland, Russia)

Asia Pacific (India, China ASEAN, Australia & New Zealand)

Japan

The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For any queries linked with the report, ask an analyst >>

https://www.futuremarketinsights.com/ask-question/rep-gb-10978

About FMI: Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us: Mr. Debashish Roy Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: sales@futuremarketinsights.com For Media Enquiries: press@futuremarketinsights.com Website: https://www.futuremarketinsights.com

[shreyas-inkwood]

Novel Products divert Attention towards the Antithrombotic Drugs Market

Since the 1930s, antithrombotic therapy has been used as the key medical therapy for treating thrombotic diseases. Studies have stated that venous or arterial thrombosis is one of the leading causes of mobility and mortality worldwide. However, the implementation of these drugs has led to one of the terrified iatrogenic illnesses. Over the years, developments have risen potential improvements in medications with regards to the ability to eradicate or cause no bleeding.

In comparison with traditional therapies, varied novel products are developed, including enhanced drugs action and clinical profiles. Moreover, the conclusion of a wide range of research with evidence has defined the functioning of Factor X that can prevent coagulation by abbreviating the formation of thrombus without the danger of bleeding. Thus, Factor X is under detailed examination to develop novel anticoagulant therapies.

Governments worldwide are formulating several healthcare policies and initiating programs to make the country healthy. The prime contributor to this attention is the growing aging population, leading to a surge in surgeries that boosted the demand for NOACS. Our estimations suggest that the global antithrombotic drugs market will witness a growth rate of 6.79% between 2019 and 2027.

Currently, the product type market is segmented into three main classes – Anticoagulants, Antiplatelet and Thrombin Inhibitors. In short, anticoagulants and antiplatelet drugs are commonly known as blood thinners, and thrombin inhibitors delay thrombin activity that prevents clot formation in the blood.

Below is the list of some Top Products from the Above Three Classes that are leading the Global Antithrombotic Drugs Market:

Xarelto (Rivaroxaban)

In terms of revenue, Xarelto is known to hold the best performance in the market. This thrombin inhibitor is part of a drug class – direct factor XA inhibitors. The product is marketed by Bayer across the globe, and another company, Jansen Pharmaceutical, markets in the United States. Currently, Xarelto is a patent-protected product that expires in 2022 and 2024, specifically in the U.S. The product is also said to be safeguarded from the threat of generic competition, therefore, to witness blooming prospects in the future.

Eliquis (Apixaban)

Eliquis is another leading factor XA inhibitor, holding a majority market share in terms of revenue. The product is marketed by two companies: Bristol-Myers Squib and Pfizer. Eliquis holds its patent protection till 2023 in the United States and by 2022 in the EU. In addition, Eliquis is also anticipated to continue its revenue lead over the coming years.

Pradaxa (Dabigatran Etexilate Mesylate)

Over a period of time, Pradaxa is one to be the most known direct thrombin inhibitor drug on the market. On the contrary, the product sale has seen a slack due to the emergence of other thrombin inhibitors. The company marketing Pradaxa is Boehringer Ingelheim. The product generated a revenue of $1.8 billion in 2015 and is projected to grow steadily in the coming years. Pradaxa patent expired on July 17, 2021.

LOVENOX (ENOXAPARIN)

Lovenox is an anticoagulant drug marketed and commercialized by Sanofi. It is low molecular weight heparin, indicated for the prophylaxis of deep vein thrombosis. It also helps prevent pulmonary embolism in patients with knee/hip replacement and abdominal surgeries or medical patients with severely restricted mobility during acute illness. However, the patent expiration of Lovenox in 2012 has led to a strong decline in its revenue sales.

Plavix (Clopidogrel)

Plavix was jointly developed and marketed by Sanofi and Bristol-Myers Squibb. The drug’s patent expired in 2012, which is responsible for the major decline in its revenues. Plavix and its generic versions earned revenues of $2.2 billion in 2015, but its revenue graph is expected to witness a further decrease in the coming years.

Conclusion

The key concern acknowledged by the operating players in the market is the safety of the antithrombotic drugs, obligated to its precarious aftermath, including liver damage, burning sensation, itching etc. Hence, the companies are striving for technological innovations to completely eradicate these allergic reactions from the drugs, making them safer.

[delicatemagazinedreamer]

Venous Thromboembolism (VTE) Devices Market Trends 2021: Growth Statistics and  Forecast 2028

Venous thromboembolism is a life-threatening medical illness that needs to be treated right away. The goal of treatment is to break up the clots and prevent them from forming again. Anticoagulants (such as unfractionated and low molecular weight heparin, as well as warfarin) are used to thin the blood, as are mechanical devices (compression stockings), and thrombolytic therapy (tissue plasminogen activator). The development of innovative oral anticoagulants (NOACs) to overcome the limitations of current treatment choices and provide improved patient care is projected to drive growth in the Venous thromboembolism (VTE) Market in the near future. Direct thrombin inhibitors (argatroban, dabigatran) inhibit factor IIa (thrombin), while factor Xa inhibitors inhibit factor Xa (rivaroxaban, edoxaban, apixaban). NOACs outperform current vitamin K antagonists in terms of pharmacology (heparin or warfarin).

These benefits include a faster onset and offset of effect, predictable pharmacokinetics, and fewer medication interactions, all of which obviate the need for regular coagulation monitoring that is required with traditional anticoagulant therapy. The Venous thromboembolism (VTE) Market is being fueled by an increase in government spending, an increase in the incidence rate of venous thromboembolism, an increase in patient awareness about therapy, and high unmet needs of present treatment choices.

Read more @ https://creativeedge16.blogspot.com/2021/12/venous-thromboembolism-vte-market.html

[omkarpatel]

Thrombin Inhibitor Market is Estimated to Witness High Growth Owing to Opportunity to Treat Conditions Related to Coagulation and Thrombotic Disorders

Thrombin inhibitors are medications used to treat and prevent blood clots by inhibiting thrombin. Thrombin is a key blood clotting protein (serine protease) that causes blood clotting by converting soluble fibrinogen into insoluble strands of fibrin. Thrombin inhibitors are used for surgical procedures to lessen bleeding and treat conditions related to coagulation problems and thrombotic disorders. The global thrombin inhibitor market is estimated to be valued at US$ 30.75 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity to treat conditions related to coagulation and thrombotic disorders is expected to boost the growth of the thrombin inhibitor market over the forecast period. Deep vein thrombosis and pulmonary embolism cases are increasing due to sedentary lifestyles resulting from increased desk jobs and less physical activity. Moreover, rising geriatric population also leads to an increase in coagulation-related conditions propelling the demand for thrombin inhibitors. For instance, according to the Centers for Disease Control and Prevention in the U.S., each year 500,000 to 600,000 Americans develop DVT or PE, and there are about 100,000 deaths annually. Thrombin inhibitors play an important role in effectively managing such conditions and improving the quality of life of patients. Porter’s Analysis Threat of new entrants: The thrombin inhibitor market has high capital requirements for R&D and manufacturing operations, which poses a barrier to entry. Strict regulations for approval also discourage new companies from entering the market. Bargaining power of buyers: The bargaining power of buyers is moderate as thrombin inhibitors have few substitutes for their intended therapeutic use. However, the presence of many established manufacturers limits buyers' influence on prices. Bargaining power of suppliers:

SWOT Analysis Strength: Well-established distribution network and brand recognition of key players. Growing prevalence of cardiovascular diseases and blood clots increases market demand. Weaknesses: Strict regulatory approvals and clinical trials lead to high costs. Potential side-effects and risks of long-term use. Opportunities: Expanding applications in new disease areas. Growing healthcare expenditure in emerging markets. Threats: Patent expiries of major drugs. Development of alternative new anticoagulant drugs. Key Takeaways The global thrombin inhibitor market is expected to witness high growth during the forecast period of 2023 to 2030 due to the increasing prevalence of cardiovascular and thrombotic disorders worldwide. Bristol Myers Squibb, Bayer AG, Sanofi S.A., Boehringer Ingelheim GmbH, Johnson & Johnson, Daiichi Sankyo Company, Limited, CSL Behring, Portola Pharmaceuticals, Inc., AbbVie Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Aspen Pharmacare Holdings Limited, Eisai Co., Ltd. Major companies are focusing on inorganic strategies such as acquisitions and collaborations for technology and pipeline enhancements.

[marketresearchhealthcarefuture]

Blood Plasma Derivatives Market Analysis By Size, Share, Segments and Regional Trends 2027

Market Research Future (MRFR) predicts that the global blood plasma derivatives market will attain the valuation of USD 58.2 billion by 2023, after reaching USD 30.5 billion in 2016. The market can achieve a CAGR of 7.52% during the forecast period (2017-2023), says MRFR.

Esteemed Players

The esteemed players in the worldwide blood plasma derivatives market include CSL Limited (Australia), Baxter International Inc. (U.S), SK Plasma (Korea), Grifols (Germany), Fusion Healthcare (India), and others.

Players like Bain Capital (U.S), Biotest AG (Germany), Octapharma AG (Germany), are also operating in the market.

Get a FREE Sample with Complete TOC @ https://www.marketresearchfuture.com/sample_request/1325

Growth Boosters and Key Barriers

Blood plasma refers to blood’s liquid component that comprises the extracellular matrix. It plays a big part in maintaining electrolyte as well as osmotic balance, and also helps prevent infection and blood disorders within the body. It contains primarily water coupled with various other components including dissolved proteins, immunoglobulin, clotting factors, glucose, hormones, and electrolytes.

Plasma derivatives can be described as the concentrates of certain proteins that need pooling of plasma from a huge number of donors. It requires over hundred plasma donations to generate enough immunoglobulin to treat an immune deficient patient for at least a year. This factor presents numerous lucrative opportunities for technological advancements for elevating plasma-derived products’ production.

Boost in demand for blood plasma derivatives has been noted on account of the massive patient pool and the lack of alternative treatments. This is believed to add to the strength of the market to a large extent. To elaborate, there is no definite cure for hemophilia at present, wherein the patient requires a lifelong infusion of plasma-derived products. Other crucial factors that have a hand in the market growth include the surge in disease awareness as well as education, rising commitment to research, and organized network of donor centers. On a different note, the high cost of treatment could act as an obstacle in the market growth.

March 2019

GCAM, Inc. has added a set of new blood plasma collection centers in Texas (U.S.) to its existing infrastructure. With these additions, the company now owns 10 plasma donation centers across the country.

Intended Audience

Blood Plasma Derivatives Companies

Research and Development (R&D) Companies

Medical Research Laboratories

Diagnostic centers

Blood transfusion centers

Academic Medical Institutes and Universities

Market Segmentation

The worldwide Blood Plasma Derivatives Market has been segmented on the basis of type, application, and end-users.

The blood plasma derivatives market, depending on the type, covers albumin, anti-thrombin, intravenous immunoglobulin (IVIG), fresh frozen plasma (FFP) and others. Other types include Factor VII, Factor IX, and Alpha 1 proteinase inhibitor concentrate.

With respect to the application, the market caters to Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, and others. Other applications covered by the report are Von Willebrand disease.

End users, as per the report, are hospitals, clinics, diagnostic centers, blood transfusion centers, and others.

Regional Insight

The worldwide blood plasma derivatives market is split into the main regions of Europe, Asia Pacific Middle East & Africa as well as North America.

Experts predict that the North America blood plasma derivatives market will surge at a CAGR of 4.25% in the coming years. The regional market is expected to increase from the value of USD 20 billion in 2016 to USD 35.50 billion by 2023. The region is noted for early approval of plasma derivatives products and rising number of fractionation plants, which works in favor of the market. The mounting awareness level pertaining to the use of plasma derivatives for infectious diseases could be another critical factor boosting the market.

Europe is reckoned to be the second-most profitable market for blood plasma derivatives, expected to rise at a CAGR of 3.8% in the years ahead. Exhaustive research on safe blood transfusion within the healthcare centers and numerous research laboratories are the chief reasons for the lucrative market in the region. In addition to the expanding geriatric population in the region, the rise in awareness about blood & plasma donation is perceived to augur well with the market in the ensuing years.

With the fastest-growth in the global blood plasma derivatives market, Asia Pacific will benefit from the prevalence of life-threatening diseases and the high awareness levels in the region. India has been identified as the strongest contender with the quickest growth rate in the region.

The market in Middle East and Africa is presumed to demonstrate consistent growth. Southern and Eastern Africa note the highest number of HIV cases, which accounts for almost 19 million people. The number of HIV cases are expected to increase rapidly in other parts of Middle East and Africa as well. These factors are expected to elevate the demand for blood plasma derivatives in the region in the years to come.

Get More Information on Blood Plasma Derivatives Market Research Report- Global Forecast To 2023 @ https://www.marketresearchfuture.com/reports/blood-plasma-derivatives-market-1325

Scope of Report

The report for Blood Plasma Derivatives market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

[jay99]

Global Fibrin Glue Market- Industry Analysis and forecast 2019-2027

Global Fibrin Glue Market size was valued US$ XX Bn. in 2019 and the total revenue is expected to grow at 12.02% through 2019 to 2027, reaching nearly US$ XX Bn.

Global Fibrin Glue Market

To know about the Research Methodology :- Request Free Sample Report

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Fibrin glue also called as fibrin sealant is a hemostatic agent, used in surgical procedure as adhesion material to close wounds by making fibrin clot. Fibrin glue is derived from human and animal blood products. Fibrin glue main ingredients contain purified thrombin (Enzyme) and purified fibrinogen (Protein).

The fibrin glue market dynamics are thoroughly studied and explained in the MMR report, which helps to understand emerging market trends, drivers, restraints, opportunities, and challenges at the global and regional level for the fibrin glue market globally. The improved healthcare industry in the developing economies provide huge growth opportunities for the global market for fibrin glue. The overall healthcare sector is undergoing rapid changes in the developing economies thanks to growing government expenditure, upsurge in the number of surgeries, rising number of hospitals, and mounting healthcare awareness. Emerging countries offer suitable opportunities for the growth of the fibrin glue market globally. In emerging economies such as Brazil, India, China, and Mexico, the government is increasing expenditure on healthcare. As per the 2014 World Bank, Brazil spent nearly 8.3% of US$ 2.456 trillion GDP on healthcare. However, the market for fibrin glue has been facing certain challenges, for instance, stringent regulatory requirements and growing minimally invasive procedures, which may hinder the growth of the global market, during 2019-2027.

By application, cardiac surgery segment was valued US$ XX Mn. in 2019 and is expected to reach US$ XX Mn. by 2027 at a CAGR of XX.30% over the forecast period. Fibrin based glue is used for hemostasis and tissue adherence throughout cardiac surgeries to avoid the loss of blood, which is one of the most serious issues encountered while acting a cardiac surgery. Likewise, the MMR report will provide an accurate prediction of the contribution of the various segments to the growth of the fibrin glue market size.

The report also offers a brief analysis of the major regions in the fibrin glue market, namely, Europe, North America, APAC, South America, and the MEA. Among this, North America accounted for the largest fibrin glue market share in 2019, with a market value of US$ XX Mn; the regional market is expected to register a CAGR of XX.10% during 2019-2027. This is attributed to the increase in the number of surgical procedures. Furthermore, APAC is likely to display a significant growth in the fibrin glue market during 2019-2027. Emerging countries like China & India are expected to play a major role in the growth of Asian fibrin glue market. A chance of pollution of glue with viruses in human is one of the disadvantages of fibrin glue which can be an inhibitor for the market for fibrin glue.

In recent years, major players in the fibrin glue market have taken several strategic measures, like facility expansions and partnerships. In 2018, a worldwide leader in advancing surgical invention, Baxter Company unveiled the latest design improvements for its fibrin sealant product. The Tisseel Prima syringe was exposed at the 2018 AAGL (American Association of Gynecologic Laparoscopists) meeting. Also, in 2019, to aid surgeons manage bleeding through surgery; Johnson & Johnson Medical Devices Companies declared that Ethicon launched VISTASEAL Fibrin Sealant (Human).

The objective of the report is to present a comprehensive analysis of the Global Fibrin Glue Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Fibrin Glue Market dynamics, structure by analyzing the market segments and projects the Global Fibrin Glue Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Fibrin Glue Market make the report investor’s guide.

FOR MORE INFO VISIT US: https://www.maximizemarketresearch.com/market-report/global-fibrin-glue-market/71575/

Scope of the Global Fibrin Glue Market: Inquire before buying

Global Fibrin Glue Market, By Application

• Cardiac surgery • Pulmonary surgery • Burn bleeding • Vascular surgeries • Orthopedic surgeries • Lacerations of liver and spleen • Neurosurgery • Plastic surgery • General surgery • Wound management Global Fibrin Glue Market, By Product

• Viral Inactivation • Autologous Donation • Recombinant Production • Others Global Fibrin Glue Market, By Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA Key players operating in Global Fibrin Glue Market

• Vivostat A/S • Kaketsuken • Johnson & Johnson • Baxter International Inc. • CSL Behring • STB Lifesaving Technologies • Zimmer Biomet Holdings, Inc. • Takeda Pharmaceutical Company Limited • Mallinckrodt Plc • Shanghai RAAS Blood Products Co. Ltd. • Hualan Biological Engineering Inc. • Bayer • Shanghai RAAS • Cryolife • Haemcure Corporation • Omrix Biopharmaceutical, Inc. • Interpore Cross.

For More Information Visit @: Maximize Market Research Company This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.